Kyowa Kirin International

What Kyowa Kirin International does

Kyowa Kirin International plc is a Scotland-registered specialty pharmaceutical company (company number SC198780, registered office at Galabank Business Park, Galashiels TD1 1QH) and a wholly-owned subsidiary of the Japan-based Kyowa Kirin Group. The company operates as the international commercial arm of the group, maintaining direct country-level commercial operations across more than twenty European jurisdictions (including Belgium, Czech Republic, Denmark, Germany, Estonia, Ireland, Spain, France, Iceland, Italy, the Baltics, Luxembourg, the Netherlands, the Nordics, Portugal, Switzerland, and the United Kingdom) and six Middle Eastern markets via a dedicated GCC office (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, UAE). Its therapeutic focus is concentrated in three areas: rare metabolic and bone/mineral disorders, intractable haematological diseases and haemato-oncology, and rare diseases.

The company's commercial portfolio centers on branded prescription biologics, with mogamulizumab—a monoclonal antibody for advanced cutaneous T-cell lymphoma (including mycosis fungoides and Sézary syndrome)—as the lead asset. Clinical evidence from the PROCLIPI real-world registry, covering 2,000+ patients across 19 countries, demonstrates longer median overall survival in mogamulizumab-treated versus non-treated advanced CTCL patients. Underlying technology emphasizes antibody engineering and cell and gene therapy development, built on more than seventy years of group-level investment in drug discovery and biotechnology innovation.

Revenue is generated through direct enterprise field sales of branded prescription pharmaceuticals to healthcare professionals and institutions, distributed through country-specific websites and a dedicated Healthcare Professionals Hub, with structured adverse-event reporting infrastructure. In March 2026, Kyowa Kirin International became a key client in the Accenture Databricks Business Group, building AI-driven solutions on Databricks' Lakebase, Genie, and Agent Bricks platforms. Leadership transitioned in November 2025 with Julie Dehaene-Puype appointed as President for the Region, succeeding Jeremy Morgan, in line with a broader global restructuring that includes a dual CEO-COO structure at the parent level.

Name

Kyowa Kirin International

Legal name

Kyowa Kirin International plc

Website

https://KyowaKirinInternational.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Kyowa Kirin International plc is the Scotland-based international commercial arm of Japan-based Kyowa Kirin Group, selling branded specialty pharmaceuticals across 26+ European and Middle Eastern countries, focused on rare metabolic, hematologic, and rare diseases.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

akta.pro secondary industries

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Specialty pharmaceuticals
• Monoclonal antibodies
• Rare disease treatments
• Oncology therapeutics
• Cell and gene therapy

Headquarters

HQ city

Scottish Borders

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: Kyowa Kirin International operates as a global specialty pharmaceutical company selling prescription medicines through traditional pharmaceutical distribution channels. Revenue is generated through the sale of branded pharmaceutical products targeting rare diseases, bone and mineral disorders, and hematology/oncology conditions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Kyowa Kirin International develops and commercializes specialty prescription medicines, including monoclonal antibodies such as mogamulizumab, for the treatment of rare metabolic diseases, intractable hematological diseases and haemato-oncology, and rare diseases. The company is also engineering next-generation antibodies and cell and gene therapies targeting high unmet medical needs.

Product overview

Kyowa Kirin International is a Japan-based Global Specialty Pharmaceutical Company with over 70 years of experience in drug discovery and biotechnology innovation. The company operates across three core therapeutic areas: Bone and Mineral (rare metabolic diseases), Intractable Haematological Diseases and Haemato-Oncology (haematology/oncology), and Rare Diseases. Their portfolio includes pharmaceutical products such as mogamulizumab, a monoclonal antibody for cutaneous T-cell lymphoma treatment. The company is actively working on developing next-generation antibodies and cell and gene therapies targeting high unmet medical needs. Kyowa Kirin International maintains operations across Europe and the Middle East through regional offices in multiple countries including the UK, Germany, France, Spain, Italy, and others.

Differentiator

Problem solved

Functional benefit

Products and services

• Mogamulizumab

Quantifiable outcome

• Longer median overall survival for CTCL patients treated with mogamulizumab vs non-treated patients

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• DatabrickscoreTechnology or Integration · 17 March 2026Kyowa Kirin International is a key client of Accenture and Databricks collaboration, developing AI-driven solutions using Databricks platforms including Lakebase, Genie, and Agent Bricks. The partnership is part of the Accenture Databricks Business Group, a dedicated unit supported by over 25,000 Databricks-trained professionals.
• AccenturecoreTechnology or Integration · 17 March 2026Kyowa Kirin International is developing AI-driven solutions with Accenture and Databricks as a key client. Accenture and Databricks launched the Accenture Databricks Business Group with over 25,000 trained professionals to help clients deploy AI applications and agents on enterprise data.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Swedish Orphan Biovitrum (Sobi): European-headquartered rare-disease specialty pharmaceutical company with a focus on hematology, immunology, and rare metabolic disorders — directly comparable to Kyowa Kirin International in therapeutic focus, geographic scope, and enterprise sales model to specialists.
• Takeda Pharmaceutical: Japan-based global specialty pharmaceutical company with a major rare-disease, hematology, and oncology franchise across Europe and the Middle East, and a comparable Japan-parent operating model with regional subsidiaries.
• Astellas Pharma: Japan-based specialty pharmaceutical company with established hematology/oncology and rare-disease assets, operating across Europe and other major markets — a peer in modality mix (antibody engineering) and EMEA go-to-market motion.
• Daiichi Sankyo: Japan-headquartered specialty pharma with a strong oncology and rare-disease pipeline (notably antibody-drug conjugates) and significant European commercial infrastructure — comparable as a Japan-rooted specialty pharma with cutting-edge biologic modalities.
• Eisai Co., Ltd. Japan-based specialty pharmaceutical company with oncology, rare-disease, and neurology focus and an established EMEA regional presence through country subsidiaries — closely aligned to Kyowa Kirin International's Japan-parent, specialty/rare-disease positioning.
• Recordati Rare Diseases: European specialty pharmaceutical group with a dedicated rare-disease business unit marketing orphan drugs across Europe and the Middle East — directly comparable in commercial scope, regulatory positioning, and enterprise sales to specialists.
• Servier: France-based global specialty pharmaceutical group with a strong oncology and rare-disease franchise distributed across Europe, the Middle East, and other regions — closely comparable in European specialty pharma scale and therapeutic focus.

Broad incumbents

• Alexion / AstraZeneca Rare Disease: Global leader in rare-disease therapeutics (complement-mediated and hematologic rare diseases), now part of AstraZeneca — comparable therapeutic areas (rare hematology) and European commercial model, with broader resources and global reach.
• Vertex Pharmaceuticals: Global specialty pharmaceutical company focused on rare diseases (cystic fibrosis, sickle cell, hematology) — a benchmark for orphan-drug commercial execution, pricing power, and pipeline expansion into cell and gene therapy.

Emerging players

• Jazz Pharmaceuticals: Ireland-headquartered specialty pharmaceutical company focused on neuroscience and hematology/oncology, including rare diseases — comparable in scale, European/EMEA commercial presence, and orphan-disease commercial model.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat4 records

Key risks1 record

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/kyowa-kirin-international-plc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kyowa Kirin International